Alphamab Oncology (STU:3NK) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3NK Alphamab Oncology STU:3NK
55 GF Score
Price €0.89
GF Value €0.83
! 4 Warning Signs
View Full Analysis

What is Alphamab Oncology Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Alphamab Oncology Quality Rank Related Terms

STU:3NK
55GF Score
Alphamab Oncology STU:3NK
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alphamab Oncology (STU:3NK) Overvalued in 2026?

Based on GuruFocus' analysis, Alphamab Oncology stock appears to be overvalued. The current stock price of €0.89 is trading 7.2% above its estimated GF Value™ of €0.83.

Key valuation signals for STU:3NK:

  • Quality Rank:
  • GF Value™: €0.83 vs. price of €0.89 (7.2% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the STU:3NK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alphamab Oncology Business Description

Other Exchanges 09966:Hong Kong
Address No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Alphamab Oncology is a biopharmaceutical company in China with a fully integrated proprietary technology platform in ADCs, bispecific antibodies, and multifunctional protein engineering. The Company is principally engaged in the research and development, manufacturing, and commercialisation of biologics of oncology. It delivers therapeutic biologics by applying its drug discovery and development capabilities. Its product portfolio includes Envafolimab (KN035), KN026, JSKN003, JSKN016, JSKN033, JSKN022, JSKN027, JSKN021, KN019, and KN046.
55GF Score

Get the complete analysis for STU:3NK

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.89
Price
€0.83
GF Value